News

The Medtronic CoreValve Evolut and the Edwards Lifesciences Sapien 3 TAVR valves.

More research is still needed, as this study only included data from a small number of patients, but TAVR was not linked to any severe adverse events or allergic reactions.

Joshua M. Hare, MD, FACC, FAHA, a professor of medicine, molecular and cellular pharmacology, and biomedical engineering, director of regenerative medicine, and director of the Interdisciplinary Stem Cell Institute (ISCI) at the University of Miami, and co-founder and chief science officer for the stem cell start-up Longeveron, explains the FDA trial for laromestrocel (Lomecel-B) to treat hypoplastic left heart syndrome (HLHS).

The new trial represents a potential breakthrough in the treatment of one of the most devastating congenital heart defects.

As mitral transcatheter edge-to-edge repair continues to gain momentum in the United States, a new study of CMS data examines what happens to patient outcomes when the procedure fails.

Evaluating LVDF with echocardiography or AI-powered electrocardiography can help identify individuals at an increased risk of developing atrial fibrillation, according to new data presented at the ASE 36th Annual Scientific Sessions.

Microbot Medical Liberty

The new Liberty System allows users to remotely deliver and manipulate guidewires and catheters during peripheral endovascular procedures.

The key figure from NEJM publication confirms the survival benefit of Impella CP increases year-over-year. Source: Møller J, et al. Long Term Outcomes of the DanGer Shock Trial. N Engl J Med 2025.

When patients present with STEMI-related cardiogenic shock, treatment with the Impella CP appears to make a positive impact that lasts for at least a decade.

Newsweek ranked the 50 best heart hospitals in the world

CMS has proposed a policy shift that would allow cardiac ablation procedures to be performed in ambulatory surgical centers. Arash Aryana, MD, PhD, a veteran cardiac electrophysiologist, explained why he is "extremely encouraged" by this proposal, highlighting several potential benefits. 

GE HealthCare Revolution Vibe CCTA

“FDA clearance comes at the perfect time, with guidelines being adopted clinically for cardiac CT and with positive reimbursement driving procedure growth," says Jean-Luc Procaccini, CEO, molecular imaging and CT.

The new drug, asundexian, is currently the subject of two multicenter Phase III studies—the OCEANIC-AF trial and OCEANIC-STROKE trial—focused on its safety and efficacy.

Thumbnail

The 35-year-old cardiologist has now been charged in a total of 10 sexual assault cases. 

Thumbnail

“These and other data support that young adults do as well as a more traditional patient population when looking at arrhythmia-free survival,” researchers wrote.

Mitral Valve Surgery from the University of Washington

“I was ready to make out my will, so this came along just at the right time,” the 76-year-old patient said. 

Around the web

Anders Gilberg, senior vice president of government affairs at the Medical Group Management Association, explains why Congress needs to renew the Medicare geographic pay adjustments in rural areas—to make payments competitive with urban areas and help retain physicians in those communities.

GE Healthcare reports Q2 revenue growth of 3% and lower than expected tariff losses at $550 million.

Hospitals are awarded Honor Roll points if they rank in one or more of the 15 specialties that U.S. News evaluates, and in one or more of the 22 procedures or conditions for patient outcomes.